Evidence for infliximab-induced reduction of serum levels of proinflammatory mediators in psoriatic arthritis - 21/08/11
Colleen Marano, PhD, Christian Antoni, MD, Friedrich-Alexander University, Erlangen, Germany; Anna Beutler, MD, Centocor, Inc., Malvern, PA, United States; Gerald Krueger, MD, University of Utah Health Sciences Center, Salt Lake City, UT, United States
Le texte complet de cet article est disponible en PDF. P2831 Dr. Marano is an employee of Centocor, Inc. Dr. Antoni is an investigator and consultant for infliximab at Centocor. Dr. Krueger is a consultant to Biogen, Genentech, and Centecor; on the sponsored speakers list for Amgen, Biogen, Genentech, and Centecor; has participated in clinical trials for each of these companies. Neither Dr. Krueger nor his family own stock in these companies. Studies have been funded by research grant from Centocor (IMPACT) or have been done by Centocor (IMPACT 2). |
Vol 52 - N° 3S
P. P204 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?